Oratz R - Search Results

1

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A. Hochster H, et al. Among authors: oratz r. Clin Cancer Res. 1997 Aug;3(8):1245-52. Clin Cancer Res. 1997. PMID: 9815806 Clinical Trial.

2

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL. Hochster H, et al. Among authors: oratz r. J Natl Cancer Inst. 1992 Nov 18;84(22):1725-30. doi: 10.1093/jnci/84.22.1725. J Natl Cancer Inst. 1992. PMID: 1433357 Clinical Trial.

3

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.

Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, Le Sher D, et al. Liebes L, et al. Among authors: oratz r. J Natl Cancer Inst. 1992 May 6;84(9):694-9. doi: 10.1093/jnci/84.9.694. J Natl Cancer Inst. 1992. PMID: 1569602 Clinical Trial.

4

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Walsh C, Blum RH, Oratz R, Goldenberg A, Downey A, Speyer JL. Walsh C, et al. Among authors: oratz r. J Cancer Res Clin Oncol. 1992;118(1):61-6. doi: 10.1007/BF01192313. J Cancer Res Clin Oncol. 1992. PMID: 1729261 Clinical Trial.

5

Survival with regional and distant metastases from cutaneous malignant melanoma.

Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J, Boyd A, Golomb FM, Ransohoff J, Dugan M, et al. Roses DF, et al. Among authors: oratz r. Surg Gynecol Obstet. 1991 Apr;172(4):262-8. Surg Gynecol Obstet. 1991. PMID: 2006449

6

Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.

Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC. Oratz R, et al. Cancer Res. 1991 Jul 15;51(14):3643-7. Cancer Res. 1991. PMID: 2065322 Clinical Trial.

7

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.

Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M, Mischak R, Spitler LE. Oratz R, et al. J Biol Response Mod. 1990 Aug;9(4):345-54. J Biol Response Mod. 1990. PMID: 2395000

8

Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine.

Oratz R, Cockerell C, Speyer JL, Harris M, Roses D, Bystryn JC. Oratz R, et al. J Biol Response Mod. 1989 Aug;8(4):355-8. J Biol Response Mod. 1989. PMID: 2754436

9

Immunogenicity of a polyvalent melanoma antigen vaccine in humans.

Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Bystryn JC, et al. Among authors: oratz r. Cancer. 1988 Mar 15;61(6):1065-70. doi: 10.1002/1097-0142(19880315)61:6<1065::aid-cncr2820610602>3.0.co;2-l. Cancer. 1988. PMID: 3342366

10

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.

Oratz R, Speyer JL, Green M, Blum R, Wernz JC, Muggia FM. Oratz R, et al. Cancer Treat Rep. 1987 Sep;71(9):877-8. Cancer Treat Rep. 1987. PMID: 3621224 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters